Accuray Announces Financing Amendments and Workforce Reduction

Accuray ( (ARAY) ) just unveiled an announcement.

On December 12 and 15, 2025, Accuray Incorporated announced amendments to its financing agreement, aimed at improving liquidity and financial flexibility. These changes include adjustments to liquidity calculations, removal of leverage conditions, and issuance of warrants to lenders. Concurrently, Accuray initiated a strategic transformation plan, including a 15% workforce reduction, expected to improve annual operating profitability by $25 million. This organizational realignment aims to enhance competitiveness and streamline operations, with restructuring costs estimated at $11 million.

The most recent analyst rating on (ARAY) stock is a Hold with a $0.96 price target. To see the full list of analyst forecasts on Accuray stock, see the ARAY Stock Forecast page.

Spark’s Take on ARAY Stock

According to Spark, TipRanks’ AI Analyst, ARAY is a Neutral.

Accuray’s overall stock score is primarily impacted by its financial performance, characterized by declining revenues, negative profitability, and high leverage. Technical analysis indicates bearish momentum, and valuation metrics are unattractive due to a negative P/E ratio. While the earnings call and corporate events highlight potential for future growth, current financial metrics and market conditions present significant challenges.

To see Spark’s full report on ARAY stock, click here.

More about Accuray

Accuray is a company dedicated to advancing radiation therapy solutions to improve patient outcomes, focusing on oncology and neuro-radiosurgery. Headquartered in Madison, Wisconsin, Accuray is committed to continuous innovation and partners with clinicians to enhance treatment delivery.

Average Trading Volume: 1,066,388

Technical Sentiment Signal: Sell

Current Market Cap: $120.1M

For detailed information about ARAY stock, go to TipRanks’ Stock Analysis page.